KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBITDA Margin: 2010-2024

Historic EBITDA Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to 12.34%.

  • Supernus Pharmaceuticals' EBITDA Margin fell 5460.00% to -31.35% in Q3 2025 from the same period last year, while for Sep 2025 it was -5.42%, marking a year-over-year decrease of 1451.00%. This contributed to the annual value of 12.34% for FY2024, which is 1321.00% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported EBITDA Margin of 12.34% as of FY2024, which was up 1,522.78% from -0.87% recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' EBITDA Margin registered a high of 33.38% during FY2020, and its lowest value of -0.87% during FY2023.
  • Moreover, its 3-year median value for EBITDA Margin was 6.91% (2022), whereas its average is 6.13%.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' EBITDA Margin plummeted by 1,854bps in 2021, and later skyrocketed by 1,321bps in 2024.
  • Over the past 5 years, Supernus Pharmaceuticals' EBITDA Margin (Yearly) stood at 33.38% in 2020, then slumped by 1,854bps to 14.84% in 2021, then plummeted by 793bps to 6.91% in 2022, then crashed by 778bps to -0.87% in 2023, then spiked by 1,321bps to 12.34% in 2024.